Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Withdrawn before enrolling · Phase 2
Conditions studied: Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
In brief
This is an open label phase 2 study to evaluate the combination of Vigil™ and nivolumab in advanced or metastatic NSCLC that is progressive on or after one prior platinum-based systemic therapy. Patients meeting study eligibility criteria will receive Vigil™ every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and nivolumab every 2 weeks. The combination of Vigil™ and nivolumab will demonstrate a higher objective response rate (ORR) than the historical ORR of single agent nivolumab in patients with advanced NSCLC.
Key facts
- Study ID
- NCT02639234
- Run by
- Gradalis, Inc.
- People needed
- 0
- Starts
- 2016-03-01
- Expected to finish
- 2017-03-01
- Last updated by the study team
- 2017-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Texas Oncology, P.A., Texas Cancer Center — Abilene, Texas, United States
- Mary Crowley Cancer Research Centers — Dallas, Texas, United States
- Cancer Care Northwest — Spokane Valley, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.